The Weekly Summary

Michelle-ObamaMay 5th – May 11th

In the general news, terrorists in Nigeria kidnapped hundreds of schoolgirls, leading to international outrage. Otherwise, the news flow was light.

In healthcare business news, Merck (MRK) announced a megadeal to sell its consumer unit to Bayer for $14 Billion. Boston Scientific (BSX) acquired IoGyn for $65M. Regeneron (REGN) partnered with Avalanche Biotechnologies, a gene therapy company. Pfizer (PFE) reported weak revenue, but met the bottom line on cost cutting. Apple Computer is getting into the smartphone medical app business. Lastly, Vivus’ (VVUS) diet pill Qsymia could face generic threats from Actavis.

On the data front, mouse studies showed that transfusions from younger mice somehow triggered stem cells to activate in the older mice, rejuvenating them. Also, Corcept (CORT) shares fell as its depression drug failed in Phase 3.

From the FDA, daily aspirin for primary prevention was shot down by the FDA. Also, Merck’s (MRK) Zontivity (vorapaxar) was approved for secondary prevention.

This entry was posted in - The Weekly Summary. Bookmark the permalink.

Leave a Reply

Your email address will not be published.